Amgen Agreement with Celgene for Otezla® In the News Amgen (AMGN) entered into an agreement with Celgene (CELG) to acquire worldwide rights to Otezla® (apremilast), the only oral, non-biologic treatment for psoriasis and psoriatic arthritis, and certain related assets and liabilities for $13.4 billion in cash. Amgen cited the benefits of this agreement as follows: A strong fit with Amgen’s long-standing expertise in inflammation and …

AstraZeneca: Farxiga for Heart Failure with Reduced Ejection Fraction  AstraZeneca (AZN) has good news. Many of them are extremely positive. However, the firm’s stock is still struggling to get this pharmaceutical company out of the oversold territory where it has been living since the beginning of the year.    Among the recent good news came the results from a Phase 3 trial using AstraZeneca’s SGLT2 inhibitor …

From Moderna  From the press release we learned that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Moderna (MRNA) investigational Zika vaccine (mRNA-1893) currently being evaluated in a Phase 1 study for the prevention of Zika virus infection in healthy adults. This is good news for

Akari Therapeutics Stock Rallied Autoimmune and inflammatory disease treatments are works in progress with some approved products demonstrating remarkable efficacy. Still there are untreated inflammatory diseases, among them are those where the complement (C5) and/or leukotriene (LTB4) systems are implicated. Akari Therapeutics (AKTX) is a small biopharmaceutical company focused on therapeutics for the orphan autoimmune and inflammatory diseases.The Company announced that the U.S. Food and …

Regeneron Product REGN-EB3 Saving Lives Regeneron (REGN) announced that an independent monitoring board ended its investigational product REGN-EB3 trial after reviewing interim mortality data from 499 patients. REGN-EB3 was found superior to rival therapy from Mapp Biopharmaceuticals (MAPP) in saving the lives in . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Palm Ebola Clinical Trial Stopped Early as Regeneron Product REGN-EB3 Therapy Shows Superiority to ZMapp in Preventing Ebola Deaths TARRYTOWN, N.Y., Aug. 12, 2019,/PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Company was informed by study investigators that a randomized, controlled trial evaluating four investigational therapies for Ebola virus infection was stopped early because REGN-EB3 . . . This content is for paid …

Amgen’s Stock Is Up Amgen (AMGN) is speeding towards reaching its true, fair value. In the Q2 financial results Amgen has beaten the most optimistic analysts’ expectations and negative investors who keep mourning the firm’s 35 years old products’ sales’ decline while ignoring the many newly approved breakthrough products with their large markets and the capability to treat diseases that had no treatments. They continued selling …

Press Release Amgen Wins Patent Case On Enbrel® (etanercept) Court Upholds Validity of Patent Claims Directed to Enbrel Preliminary Injunction to Remain in Place THOUSAND OAKS, Calif., Aug. 9, 2019, /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. District Court for the District of New Jersey has ruled in Amgen's . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Nektar Therapeutics Story Everything was going well with Nektar Therapeutics (NKTR) stock during the Conference call regarding the firm’s Q2 financial results. (See the firm's press release under our Impacting News column). Following the Conference call the company unveiled that some of the patients treated in . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Nektar Press Release Nektar Therapeutics Results for Q2 of 2019 Nektar Therapeutics (Nasdaq: NKTR) reported its financial results for the second quarter ended June 30, 2019. Cash and investments in marketable securities at June 30, 2019 were $1.8 billion as compared to $1.9 billion at December . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

 The News Prohost Was Waiting for to Post Its Special Letter Prohost has one eye on the development-stage biotech and biopharmaceutical companies' scientific fundamentals and accomplishments as well as the financial results on the revenue-generating firms. Prohost has the second eye on the market performance, its volatility and the possible reasons it sinks every other day, or every other week, in calmer days during a …

Rhythm Pharmaceuticals From Rhythm Pharmaceuticals (RYTM) we learned that positive, top-line results from two pivotal Phase 3 clinical trials evaluating setmelanotide, for pro-opiomelanocortin (POMC) and leptin receptor (LEPR) deficiency obesities, have met their primary endpoints and all key secondary endpoints. The product demonstrated a statistically significant and clinically meaningful effect on weight loss and reductions in insatiable hunger, or hyperphagia, in patients with POMC and LEPR deficiency …

What Have We Learned from the Market's Recent Stock Moves? Well. Did we learn anything from what happened in the stock market and the reversal that started near the end of yesterday and occurred today? Listening to Larry Kudlow, the Director of the National Economic Council, as well as other academic economists and analysts all the while watching the way the market crashed yesterday and …

In This Column Every day thousands of press releases are issued about biotechnology and pharmaceutical firms. Only a few of these press releases have any impact, whether it be positive or negative, on the firms' that are the subject of these press releases. Prohost's Impacting News column will contain only those press releases that have news with a tremendous impact on the firms' that are …

Prohost has just finished a very hard task; evaluating its best picks from the biotechnology and biopharmaceutical sectors. In this evaluation of hand-selected stocks, Prohost did not consider the negotiation between the U.S. and China a serious factor that could affect the biotech stocks’ values. We do, however, consider the US/China negotiations extremely important towards reaching a fair solution that satisfies the people in both …

Nektar Therapeutics We believe that Nektar Therapeutics (NKTR) is undervalued. We base this on the firm’s technological capability. Its current pipeline is filled with promising products. Today we learned that the U.S. FDA granted Nektar’s and Bristol-Myers Squibb’s . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

RegenxBio License Agreement with Pfizer RegenxBio (RGNX) announced a license agreement with Pfizer (PFE). Under the terms of the agreement RegenxBio has granted Pfizer a non-exclusive worldwide license, with rights to sublicense, to RegenxBio’s NAV AAV9 vector for the development and commercialization of gene therapies for Friedreich’s ataxia (FA). The most common hereditary ataxia (neurological lack of muscle coordination). RegenxBio will receive an upfront payment and has …

Amgen Contrary to our expectations Amgen’s (AMGN) shares declined more than 10% in 2019, instead of rallying. Part of the decline followed the threat of devastating the large drug creators and developers by lowering the high prices of drugs. Amgen’s stock loss can also be attributed to the pressure exerted by negative investors on the stock.   Today, after . . . This content is for …

Gilead Sciences Activities There is no doubt that Gilead Sciences (GILD) is doing whatever it takes to expand, improve and upgrade its pipeline products. For the last couple of months, each and every week, we heard news about collaborations with some companies and investment in others as well as licensing products from large, medium-sized and small firms. In less than ten . . . This content is for …

Halozyme and argenx Collaboration argenx (ARGX) dosed the first subject in phase 1 clinical trial for the safety, pharmacokinetics, and pharmacodynamics of its product efgartigimod plus Halozyme’s (HALO) drug delivery technology ENHANZE®. The drug aims at treating severe autoimmune diseases including myasthenia gravis (MG), immune thrombocytopenia (ITP)and skin blistering diseases.    We find it good news that this first clinical trial has been initiated in a …